Preparation and Preliminary Evaluation of Technetium-99m-Labeled Fragment E1 for Thrombus Imaging

• Published in: The Journal of nuclear medicine (1978) Vol. 33; no. 5; pp. 710 - 715
• Main Authors: Knight, Linda C, Abrams, Michael J, Schwartz, David A, Hauser, Marguerite M, Kollman, Monica, Gaul, Forrest E, Rauh, Donald A, Maurer, Alan H
• Format: Journal Article
• Language: English
• Published: United States Soc Nuclear Med 01.05.1992
• Subjects: Animals; Dogs; Fibrin Fibrinogen Degradation Products; Fibrinogen - chemical synthesis; Humans; Isotope Labeling - methods; Organotechnetium Compounds - chemical synthesis; Rabbits; Radionuclide Imaging; Thrombophlebitis - diagnostic imaging; Time Factors
• ISSN: 0161-5505; 1535-5667

Fragment E1 labeled with 123I has been previously shown to permit imaging of thrombi in patients within as little as 20 min after injection. Because of the relatively rapid localization and blood disappearance of this protein, 99mTc would be the most clinically acceptable radionuclide for labeling Fragment E1. In this study, human fragment E1 was derivatized with a hydrazino nicotinate function to permit radiolabeling with reduced technetium. The modification reaction was carried out while the fragment E1 was protected in a complex, so that the modification occurred in nonfunctional regions of the fragment E1 molecule. After radiolabeling with 99mTc, the modified fragment E1 retained its functional activity, as judged by its binding to fragment DD in vitro. The ability of 99mTc-fragment E1 to produce images of venous thrombi was demonstrated in animal models. Images were focally positive within 20 min to 1 hr after injection. Thrombus-to-blood ratios exceeded those from 125I-fibrinogen in the same animals. This method of labeling appears to provide an alternative radiolabel to 123I without compromising the function of fragment E1.